ライフサイエンスコーパス: hypertonic

1 High NaCl is hypertonic.

2 multicenter, randomized, controlled trial of hypertonic (7%) versus isotonic (0.9%) saline inhaled tw

3 Whereas acute hypertonic activation of OVLT neurons critically depends

4 hotobleaching experiments indicate that both hypertonic and hypotonic conditions reduce the mobility

5 drug retention in colorectal tissue, whereas hypertonic and isotonic enemas provided markedly reduced

6 eover, reducing tension by exposing cells to hypertonic buffer shifts the onset of contraction to occ

7 an cell types are routinely exposed to acute hypertonic challenge and shrink.

8 y in a variety of cell types at the onset of hypertonic challenge.

9 tilbene-disulfonic acid) but decreased under hypertonic conditions (by addition of 300 mOsm mannitol)

10 In eukaryotes, exposure to hypertonic conditions activates a MAPK (Hog1 in Saccharo

11 Both hypo-and hypertonic conditions impose an increased curvature, whe

12 lyte, taurine synthesis was stimulated under hypertonic conditions in neurons.

13 ition of clathrin-mediated endocytosis using hypertonic conditions or the small molecule inhibitor, P

14 activity in oocytes under both isotonic and hypertonic conditions to the same level as in water-inje

15 kidney cells were treated under isotonic or hypertonic conditions with the nitric oxide donor S-nitr

16 this nucleus during isotonic and short-term hypertonic conditions, is an example of a modulator that

17 caspase-1 is activated in macrophages under hypertonic conditions.

18 r basis of a new mechanism for responding to hypertonic conditions.

19 tical micellar concentration, and even under hypertonic conditions.

20 orter-A reporter activity under isotonic and hypertonic conditions.

21 bstantial reduction in AQP1 expression under hypertonic conditions.

22 ion in the inner medulla of the kidney under hypertonic conditions.

23 of different levels of gene expression under hypertonic conditions.

24 pressing SDH transcriptional activity during hypertonic conditions.

25 duct (IMCD3) cells grown under isotonic and hypertonic conditions.

26 orylation of MAP kinases (ERK1/2, p38) under hypertonic conditions.

27 rmed on NP cells with TonEBP knockdown under hypertonic conditions.

28 cells exposes them to unphysiological (hypo/hypertonic) conditions.

29 al, A; soft/hypotonic, B; borderline, C; and hypertonic, D.

30 e was admitted to hospital with weight loss, hypertonic dehydration, and metabolic acidosis.

31 Hypertonic dextrose injections (prolotherapy) is an emer

32 ) cells are recruited to the skin, sense the hypertonic electrolyte accumulation in skin, and activat

33 We found that strongly hypotonic and hypertonic enemas caused rapid systemic drug uptake, whe

34 chanism in teleost fish naturally exposed to hypertonic environments.

35 ncrease their chances of survival to another hypertonic episode.

36 stress by exposure to hypoxia, hypothermia, hypertonic feedings, and lipopolysaccharide, with some p

37 Hypertonic fluids restore cerebral perfusion with reduce

38 cular veins: 0.2% polidocanol diluted in 70% hypertonic glucose (HG) (group 1) vs 75% HG alone (group

39 her 0.9% NaCl [isotonic (ISO)] or 3.0% NaCl [hypertonic (HYPER)].

40 Water-loss dehydration (hypertonic, hyperosmotic, or intracellular dehydration)

41 The Saline Hypertonic in Preschoolers (SHIP) Study was a randomised

42 ic site in the CCL2 promoter is required for hypertonic inducibility.

43 sed with hypertonicity and was necessary for hypertonic induction of target genes IL6, TNF, and NOS2

44 ese results suggest that the skin contains a hypertonic interstitial fluid compartment in which MPS c

45 tatory and pressor response than infusion of hypertonic mannitol/sorbitol.

46 Hypertonic media significantly decreased SC cell volume

47 s in the OMCD was significantly decreased in hypertonic medium (a normal milieu for the medulla) but

48 eptor-mediated endocytosis by treatment with hypertonic medium prevented PRV entry.

49 ansepithelial reabsorption of water into the hypertonic medullary interstitium mediated by collecting

50 inA 500 U or 1000 U or placebo into the most hypertonic muscle group among the elbow, wrist, or finge

51 urons display an increased discharge to both hypertonic NaCl (+7.5 mm) and mannitol (+15 mm).

52 ons were excited by bath application of both hypertonic NaCl and AngII.

53 discharge to intracarotid injection of both hypertonic NaCl and AngII.

54 ABSTRACT: Systemic or central infusion of hypertonic NaCl and other osmolytes readily stimulate th

55 rotid or intracerebroventricular infusion of hypertonic NaCl evokes a greater increase in OVLT neuron

56 tricular infusion or local OVLT injection of hypertonic NaCl increases lumbar sympathetic nerve activ

57 ng directly to the PVN (i.e. CTB-ir), graded hypertonic NaCl infusions again produced graded increase

58 es that expressed Fos-ir in responses to ICA hypertonic NaCl infusions was greater in the DC (P < 0.0

59 atment of HNF-1beta mutant mIMCD3 cells with hypertonic NaCl inhibited the induction of osmoregulated

60 First, acute intravenous infusion of hypertonic NaCl or AngII produced anatomically distinct

61 e majority of OVLT neurons are responsive to hypertonic NaCl or mannitol.

62 ings revealed that intracarotid injection of hypertonic NaCl produced a concentration-dependent incre

63 In contrast, central infusion of hypertonic NaCl produces a greater increase in arterial

64 l osmoreceptor; however, central infusion of hypertonic NaCl produces a greater sympathoexcitatory an

65 However, hypertonic NaCl stimulates a greater increase in dischar

66 bsets of OVLT neurons respond differently to hypertonic NaCl versus osmolarity and subsequently regul

67 neurons may sense or respond differently to hypertonic NaCl versus osmolarity.

68 8) displayed a greater discharge response to hypertonic NaCl vs mannitol.

69 d shape changes in response to extracellular hypertonic or hypotonic challenges.

70 wall along the filament, and varied it with hypertonic or hypotonic solutions.

71 nt candying treatment in a range of hypo and hypertonic osmotic solutions for critical transport prop

72 vity from electrophysiological recordings in hypertonic P18 kits decreased only in unmyelinated fiber

73 nce studies revealed increased urine volume, hypertonic plasma, polydipsia, and impaired urinary conc

74 Hypertonic saline (7.5%) treatment significantly attenua

75 irway dehydration could be reversed, we used hypertonic saline (HS) as an osmolyte to rehydrate ASL.

76 , and efficacy of preventive inhalation with hypertonic saline (HS) compared with isotonic saline (IS

77 urrent evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronch

78 Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS)

79 n, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emerge

80 produced by a rehydrating treatment based on hypertonic saline (HS), a current CF clinical treatment.

81 Hypertonic saline (HTS) is an accepted treatment for tra

82 Inhaled hypertonic saline (HTS) treatment is used to improve lun

83 Three percent hypertonic saline (HYS) has been suggested as a means of

84 uced in rats by episcleral vein injection of hypertonic saline (N = 30).

85 S + VH + VEH) or 80 mL/kg normal saline with hypertonic saline (RESUS + VH + HTS).

86 atients received 4 mL of 3% sodium chloride (hypertonic saline [HS group]) or 0.9% sodium chloride (n

87 ular action principle in mechanistic detail: Hypertonic saline acts via metalloproteinase 9 (MMP9).

88 The use of therapeutic interventions such as hypertonic saline administration and decompressive crani

89 easured over 4 h and again at 24 h following hypertonic saline administration.

90 e lung injury in wild-type mice treated with hypertonic saline after cecal ligation and puncture was

91 Osmotherapy with hypertonic saline ameliorates cerebral edema associated

92 ere treated with different concentrations of hypertonic saline and endotoxin of Escherichia coli O111

93 arch has demonstrated an association between hypertonic saline and hyperchloremia, limited data exist

94 Both hypertonic saline and mannitol appear to lower intracran

95 Hypertonic saline and mannitol are used less in infants

96 outcome was hospital billing for parenteral hypertonic saline and mannitol use, by day of service.

97 ation, and administrations schedule for both hypertonic saline and mannitol.

98 n Brown Norway rats (N = 26) by injection of hypertonic saline and monitored for 5 weeks.

99 mber of studies show the cellular effects of hypertonic saline and no studies, to our knowledge, have

100 fibrillary acidic protein immunostaining in hypertonic saline and normal saline treated rats, and un

101 The intervention arm prepared hypertonic saline and performed HSNIG.

102 active treatment group (n = 158) received 7% hypertonic saline and the control group (n = 163) receiv

103 emic encephalopathy and early treatment with hypertonic saline are critical for successful outcomes.

104 We used perineurial injection of hypertonic saline as a tool to open the perineurial barr

105 Treatment with 7.5% hypertonic saline attenuated blood-brain barrier disrupt

106 via the perivascular pool of aquaporin-4, 2) hypertonic saline attenuates blood-brain barrier disrupt

107 ical role in water egress from brain; and 3) hypertonic saline attenuates blood-brain barrier disrupt

108 tested the hypothesis that osmotherapy with hypertonic saline attenuates cerebral edema following ex

109 Inhaled hypertonic saline attenuates postshock acute lung injury

110 ly higher (88%) than in animals treated with hypertonic saline before cecal ligation and puncture (50

111 23.4% hypertonic saline bolus administration.

112 rapy relies on inhaled deoxyribonuclease and hypertonic saline but does not address the elastolytic d

113 These data indicate that hypertonic saline can modulate gammadeltaT cell function

114 Hypertonic saline causes increased hydraulic conductivit

115 to 116 traits assessed through blood tests, hypertonic saline challenge tests, questionnaires, and s

116 ars with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not

117 We investigated the hypothesis that bolus hypertonic saline decreases cerebral edema in severe hep

118 Hypertonic saline decreases intestinal edema and improve

119 Hypertonic saline did not reduce nerve density, but did

120 Inhaled hypertonic saline enhances mucociliary clearance, improv

121 se data demonstrate that 1) osmotherapy with hypertonic saline exerts antiedema effects via the periv

122 We tested the hypothesis that hypertonic saline exerts its antiedema effect by promoti

123 ock (shock) or traumatic brain injury (TBI), hypertonic saline failed to improve survival.

124 We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation wi

125 Hypertonic saline given to children with bronchiolitis i

126 On average, LCI decreased in the hypertonic saline group (n = 12) by 1.19 z-scores units

127 re enrolled and randomly assigned, 76 to the hypertonic saline group and 74 to the isotonic saline gr

128 Six participants in the hypertonic saline group had ten serious adverse events a

129 eported were cough (two patients [3%] in the hypertonic saline group vs three [4%] in the isotonic sa

130 In contrast in alpha-Syn(-/-) mice, hypertonic saline had no effect on the postischemic edem

131 randomized to receive either 7.2% saline/6% hypertonic saline hydroxyethyl starch (4 mL/kg) or vehic

132 y resuscitation, which was not influenced by hypertonic saline hydroxyethyl starch administration.

133 ing results in other models of brain injury, hypertonic saline hydroxyethyl starch failed to improve

134 This might explain why hypertonic saline hydroxyethyl starch has failed to impr

135 ocampal CA1 and neocortex with no effects of hypertonic saline hydroxyethyl starch on neuronal surviv

136 Hypertonic saline hydroxyethyl starch treatment resulted

137 Inhaled hypertonic saline improved the LCI(2.5) in children aged

138 Bolus 23.4% hypertonic saline improves surveillance neuromonitoring

139 , and show potentially beneficial effects of hypertonic saline in acute cervical SCI.

140 The Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE

141 Early and continuous infusion of hypertonic saline in patients with severe cerebrovascula

142 ing a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with a

143 50 patients with hyponatremia who underwent hypertonic saline infusion.

144 Hypertonic saline inhalation acutely reduced non-cystic

145 ratio of Mean Expiratory Flow after 240s of hypertonic saline inhalation with respect to the age- an

146 (Forced Expiratory Flow Volume after 240s of hypertonic saline inhalation; p = 4.81*10(-4)) and CD14

147 Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13

148 s were tracked across painful (intramuscular hypertonic saline injection) and non-painful (baseline,

149 ncreased saline intake after dehydration and hypertonic saline injection.

150 eurons were activated by fluid satiation and hypertonic saline injection.

151 IOP elevation was induced in rats by hypertonic saline injections into episcleral veins.

152 l IOP elevation was produced by injection of hypertonic saline into the episcleral veins.

153 was raised in brown Norway rats by injecting hypertonic saline into the limbal venous system.

154 was raised in Brown Norway rats by injecting hypertonic saline into the limbal venous system.

155 weeks following these injections we injected hypertonic saline intraperitoneally into the rat.

156 Hypertonic saline is currently being used in the treatme

157 Evidence for other treatments such as hypertonic saline is evolving but not clearly defined ye

158 We found that hypertonic saline is more effective than mannitol for th

159 Inhaled hypertonic saline is recommended as therapy for patients

160 Hypertonic saline is used predominantly, yet there remai

161 Nine reported that hypertonic saline lowered intracranial pressure and two

162 igible trials, but our findings suggest that hypertonic saline may be superior to the current standar

163 en patients with 18 administrations of 23.4% hypertonic saline met inclusion criteria.

164 Hypertonic saline mitigates intestinal edema development

165 non-blinded, randomised controlled trial of hypertonic saline nasal irrigation and gargling (HSNIG)

166 our findings and to evaluate the effects of hypertonic saline on functional outcomes.

167 The beneficial effects of hypertonic saline on neuronal survival and on cerebral b

168 We aimed to assess the effect of inhaled hypertonic saline on the lung clearance index (LCI(2.5))

169 onfirmed enrolment eligibility to inhaled 7% hypertonic saline or 0.9% isotonic saline nebulised twic

170 Hypertonic saline or co-loaded cargo was found to preven

171 Treating acidic ASL with hypertonic saline or heparin largely reversed the increa

172 mic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared

173 Of the 1,854 patients who received hypertonic saline or mannitol for >/= 2 days in the firs

174 yet there remains disagreement about whether hypertonic saline or mannitol is more effective.

175 umin) or crystalloids (n = 1443; isotonic or hypertonic saline or Ringer lactate solution) for all fl

176 ore fluid in response to either subcutaneous hypertonic saline or water deprivation with partial rehy

177 e interval, -1.6 to 5.7), with both favoring hypertonic saline over mannitol.

178 Nebulized hypertonic saline reduced inflammation (cytokine-induced

179 Delayed treatment of hypertonic saline resulted in the greatest reduction in

180 A3 antagonists could improve the efficacy of hypertonic saline resuscitation by reducing side effects

181 he effect of A3 receptors on the efficacy of hypertonic saline resuscitation was assessed in A3 recep

182 Randomized trials have suggested that hypertonic saline solutions may be superior to mannitol

183 n (LHSS) reward if rats are denied access to hypertonic saline solutions.

184 one either by a water deprivation test or by hypertonic saline stimulation together with copeptin (or

185 Highly concentrated hypertonic saline such as 23.4% provides a small volume

186 ed concentrations of menthol, capsaicin, and hypertonic saline that evoked comparable levels of nocif

187 cardiopulmonary resuscitation: 1) continuous hypertonic saline therapy maintained to achieve serum os

188 Intraperitoneal administration of hypertonic saline to the rat supraoptic nucleus (SON) in

189 Effects of the timing of hypertonic saline treatment administration on tissue los

190 de values should be monitored closely during hypertonic saline treatment as moderate elevations may i

191 c arrest/cardiopulmonary resuscitation, 7.5% hypertonic saline treatment did not attenuate water cont

192 Results show that hypertonic saline treatment reduced tissue loss that cor

193 rphonuclear neutrophils are activated before hypertonic saline treatment.

194 comes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Sc

195 ating that there is a therapeutic window for hypertonic saline use after traumatic brain injury.

196 Hypertonic saline use increased and mannitol use decreas

197 %; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; diff

198 At 48 weeks, treatment with hypertonic saline was associated with a significant decr

199 In the study group, nebulized hypertonic saline was delivered at the end of the shock

200 Volumes before and after 23.4% hypertonic saline were compared with Wilcoxon signed ran

201 were randomized to control (with and without hypertonic saline) and mesenteric venous hypertension wi

202 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initi

203 , dextran, gelatin, hydroxyethyl starch, and hypertonic saline).

204 on-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p

205 nt isotonic and hypotonic challenges, and to hypertonic saline, an effective therapy for mucus hydrat

206 s: 4 followed a nebulization technique using hypertonic saline, and 2 followed a chest or abdomen mas

207 3% (2,069 of 6,238) of the patients received hypertonic saline, and 40% (2,500 of 6,238) received man

208 % with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P = .88

209 addition, vogue methods such as hypothermia, hypertonic saline, and aggressive surgical decompression

210 nd ventricular volumes increased after 23.4% hypertonic saline, consistent with a reduction in brain

211 One of these treatments, hypertonic saline, is already in use, whereas others are

212 s over whether use of nebulized epinephrine, hypertonic saline, or bronchodilators should be routinel

213 mL vs. 3342 +/- 859 pg/mL, shock vs. shock + hypertonic saline, p = .006).

214 luid vs. 230 +/- 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a mat

215 ing treatment with continuous IV infusion 3% hypertonic saline, with moderate hyperchloremia independ

216 e, this study focused on the hypothesis that hypertonic saline-induced improvements in histological o

217 tasis cohort, spontaneously expectorated and hypertonic saline-induced sputa were collected, and mucu

218 For hypertonic saline-treated patients, mechanical ventilati

219 on was not different between 0.9% saline and hypertonic saline-treated wild-type mice.

220 ly, mortality in wild-type mice with delayed hypertonic saline-treatment was significantly higher (88

221 of 0.9% saline or various concentrations of hypertonic saline.

222 ently with nebulized racemic epinephrine and hypertonic saline.

223 CH selected the nebulization technique using hypertonic saline.

224 dverse effects theoretically associated with hypertonic saline.

225 uced in rats by episcleral vein injection of hypertonic saline.

226 nse after an intraperitoneal injection of 1M hypertonic saline.

227 , but only one directly compared mannitol to hypertonic saline.

228 s that may be up-regulated with edema and/or hypertonic saline.

229 IOP produced by episcleral vein injection of hypertonic saline.

230 urface, which was significantly augmented by hypertonic saline.

231 intracranial disease should be treated with hypertonic saline.

232 eater than in wild-type mice pretreated with hypertonic saline.

233 teric pain challenge with an injection of 5% hypertonic saline.

234 Continuous IV infusion 3% hypertonic saline.

235 es adopted the approach of giving a bolus of hypertonic saline.

236 ients treated with continuous IV infusion 3% hypertonic saline.

237 , 4 [3-6] to 7 [6-9]; p = 0.008) after 23.4% hypertonic saline.

238 ons of patients with severe TBI (GOSE </=4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.

239 e 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic sali

240 Survival at 28 days was 74.3% with hypertonic saline/dextran, 75.7% with hypertonic saline,

241 suscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline,

242 ine had no effect on the postischemic edema (hypertonic saline: 80.3% +/- 0.7%; 0.9% saline: 80.3% +/

243 normal saline; 2-TBI, normal saline; 3-TBI, hypertonic saline; 4-TBI, 100mM NaLac, 5-TBI, 500 mM NaL

244 have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency

245 tes global translation levels in response to hypertonic shock.

246 moter of vWF gene, suggesting involvement of hypertonic signaling in vWF up-regulation.

247 /- 0.5 to 150.2 +/- 1.3 mmol/L and activates hypertonic signaling, evidenced from increased expressio

248 lar rarefaction and the lack of any observed hypertonic skin Na(+) excess, but the lymphatic drainage

249 ory responses after intravenous infusions of hypertonic sodium lactate.

250 ersibly manipulate the appetitive value of a hypertonic sodium solution while measuring phasic dopami

251 they directly compared equiosmolar doses of hypertonic sodium solutions to mannitol for the treatmen

252 ster stimulation indeed affects responses to hypertonic solution in a supralinear manner.

253 Finally, we found that treatment with a hypertonic solution mimicked the effect we observed with

254 were rescued when the mutant was grown in a hypertonic solution, indicating that FTT_0924 is require

255 le to no detectable epithelial damage, while hypertonic solutions caused significant damage, includin

256 Cells shrank when superfused with hypertonic solutions to a minimum relative cell volume o

257 er train stimulation and dual application of hypertonic solutions) also reveal no abnormalities.

258 ial cells to volume regulate when exposed to hypertonic solutions, and furthermore to identify the io

259 Because of the potential benefits of hypertonic solutions, it is hypothesized that hydroxyeth

260 In isotonic and hypertonic solutions, rNDV displays pleomorphism and con

261 sotonic (physiologic salt concentration) and hypertonic solutions.

262 state model to synaptic responses induced by hypertonic solutions.

263 ial, lateral, and central-in physiologic and hypertonic solutions.

264 by the immersion of the biological tissue in hypertonic solutions.

265 The responses to equi-osmotic infusions of hypertonic sorbitol were significantly smaller.

266 For the method, a hypertonic stimulus was designed to create volume differ

267 Based on the method, a microfluidic hypertonic stimulus-based impedance flow cytometry chip

268 found for the zinc-finger protein ZAC1 under hypertonic stress (219-fold, p < 0.001).

269 ngly suggest that ZAC1 is up-regulated under hypertonic stress and negatively regulates expression of

270 at coordinates the intracellular response to hypertonic stress but was not previously implicated in t

271 A 450 mOsm hypertonic stress elicited 2-fold Ca2+ transients that w

272 We previously found that hypertonic stress increases PIP(2) by selectively activa

273 Hypertonic stress induced in inner medullary (IMCD3) cel

274 Hypertonic stress induced the eIF2alpha phosphorylation-

275 ropose that eIF2alpha phosphorylation during hypertonic stress promotes apoptosis by sequestration of

276 tion was higher during oxidative stress than hypertonic stress, in agreement with a dramatic decrease

277 mimic of diacylglycerol and PKC activator), hypertonic stress, lysophosphatidic acid (LPA)-induced G

278 ompare tRNA cleavage patterns in response to hypertonic stress, oxidative stress (arsenite), and trea

279 hysiological stimuli of ectodomain cleavage--hypertonic stress, phorbol ester, or activation of G-pro

280 ddition of bacterial sphingomyelinase, or by hypertonic stress, S358 is rapidly dephosphorylated.

281 the transcriptional activation of aqp1 under hypertonic stress, we examined the role of the transcrip

282 Hypertonic stress-elicited TRPV1 channel stimulation med

283 cal PKC was required for TPA-induced but not hypertonic stress-induced cleavage of all EGF family lig

284 Hypertonic stress-induced dephosphorylation is blocked b

285 response shared by all eukaryotes exposed to hypertonic stress.

286 n, but it blocked NRG release in response to hypertonic stress.

287 ase in AQP1 luciferase-driven activity under hypertonic stress.

288 lationship also occurs in kidney cells under hypertonic stress.

289 motic stabilizer and compatible solute under hypertonic stress.

290 issociation of mRNA stress granules (SGs) in hypertonic-stressed cells and the role of compatible osm

291 oked by local stimulation, or osmotically by hypertonic sucrose application, were diminished, disappe

292 Hypertonic sucrose inhibited KCa3.1 endocytosis and resu

293 mediated pathway, such as chlorpromazine and hypertonic sucrose medium.

294 on of Thr-353/354 was not affected by either hypertonic sucrose or dynasore, which prevent receptor i

295 s as measured by stimulation of release with hypertonic sucrose, or alter the rate of vesicle priming

296 s by fitting release kinetics in response to hypertonic sucrose.

297 the potential osmotic forces exerted by any hypertonic tissue Na(+) excess.

298 asis of nucleus pulposus (NP) cells in their hypertonic tissue niche.

299 Changing from a hypertonic to isotonic medium (relative hypotonicity) de

300 n contrast, isotonic and secretion-inducing (hypertonic) vehicles led to non-uniform, poor surface co

301 expression of recombinant proteins, using a hypertonic vesiculation buffer containing chloride salts